About Genoskin
Genoskin is a company based in Toulouse (France) founded in 2011. Genoskin has raised $5.4 million across 5 funding rounds from investors including BNP Paribas, Crédit Agricole and Crédit Agricole. Genoskin offers products and services including NativeSkin, HypoSkin, InflammaSkin, and WoundSkin. Genoskin operates in a competitive market with competitors including Reaction Biology, ImmunoSCAPE, PhenoVista, Discovery Biomed and BCI Pharma, among others.
- Headquarter Toulouse, France
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genoskin Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5.4 M (USD)
in 5 rounds
-
Latest Funding Round
$5.4 M (USD), Series A
Sep 16, 2025
-
Investors
BNP Paribas
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Genoskin
Genoskin offers a comprehensive portfolio of products and services, including NativeSkin, HypoSkin, InflammaSkin, and WoundSkin.
Ex vivo human skin platform for pharmaceutical and cosmetic testing
Model for hypersensitivity and inflammation studies
Platform for immune response and skin inflammation research
Ex vivo model for wound healing and infection studies
People of Genoskin
Unlock access to complete
Funding Insights of Genoskin
Genoskin has successfully raised a total of $5.4M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $5.4 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Genoskin
Genoskin has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include BNP Paribas, Crédit Agricole and Crédit Agricole.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Genoskin
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genoskin
Investment portfolio details for Genoskin
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Genoskin
Detailed financials for Genoskin
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genoskin Comparisons
Peer comparison for Genoskin
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genoskin
Genoskin operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Reaction Biology, ImmunoSCAPE, PhenoVista, Discovery Biomed and BCI Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling
|
|
| Locked | Locked | Locked |
High-dimensional immune profiling services are delivered via proprietary platform.
|
|
| Locked | Locked | Locked |
A CRO that provides phenotypic assay development and screening services.
|
|
| Locked | Locked | Locked |
Custom human cell engineering and drug discovery services are provided.
|
|
| Locked | Locked | Locked |
Contract research services in cancer and neuroinflammation are offered.
|
|
| Locked | Locked | Locked |
Specialised CRO offering a range of screening platforms for cardiac safety testing, ion channel profiling and in vitro HTS screening
|
Detailed competitors of Genoskin
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genoskin
Complete news archive for Genoskin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genoskin
Genoskin was founded in 2011 and raised its 1st funding round 7 years after it was founded.
Genoskin is headquartered in Toulouse, France. It is registered at Toulouse, Occitanie, France.
Genoskin is a funded company, having raised a total of $5.4M across 5 funding rounds to date.
Genoskin, founded as a spin-off of from the French National Center for Scientific Research (CNRS) and The Paul Sabatier University in Toulouse is engaged in the development of ex vivo human skin models for preclinical efficacy and toxicity testing of potential drug candidates and might help in reducing the use of lab animals. The company claims to keep real human skin tissue alive for 7 days in human skin models and that they are the closest alternative to in vivo clinical testing. The company claims that its human skin collection process is as per the Declaration of Helsinki. The company has a BSL 2 cell culture rooms and 3D imaging technologies. They have proprietary human skin models such as Oncoskin, which can be used to study melanoma and Hyposkin to study subcutaneous injections.
Genoskin's top competitors include ImmunoSCAPE, Quantumcyte and Reaction Biology.
Genoskin offers NativeSkin, HypoSkin, InflammaSkin, and WoundSkin.
Genoskin has 9 investors. Key investors include BNP Paribas, Crédit Agricole, Crédit Agricole, Caisse D Epargne, and Bpifrance.